GHR and growth delay due to insulin-like growth factor type 1 deficiency: Epidemiological evidence demonstrated that patients affected by Laron syndrome, a disease characterized by congenital IGF1 deficiency, due to the occurrence of homozygous mutations in the growth hormone receptor (GHR) or GH-induced intracellular signaling, do not develop cancer [58,59].